Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an
Analyst Day in New York City on Tuesday, December 4, 2012 from 10:15
a.m. to 12:00 p.m. Eastern Time (7:15 a.m. to 9:00 a.m. Pacific Time) at
the Concierge Conference Center, located at 780 Third Avenue.
The program will include a discussion of the following topics:
Presentations will be given by Ligand's senior management team, and the
program will also feature a presentation relating to Captisol®-enabled
MDCO-157 by Simona Skerjanec, Vice President, Chest Pain Care Pathway at
Ligand partner The Medicines Company.
The presentations will be webcast liv and can be accessed at www.ligand.com.
A replay of this webcast will be available for 90 days following the
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company that develops and acquires assets
it believes will generate royalty revenues and, under its lean corporate
cost structure, produce sustainable profitability. Ligand has a diverse
asset portfolio addressing the unmet medical needs of patients for a
broad spectrum of diseases including thrombocytopenia, multiple myeloma,
diabetes, hepatitis, muscle wasting, dyslipidemia, anemia, and
osteoporosis. Ligand's Captisol® platform technology is a
patent protected, chemically modified cyclodextrin with a structure
designed to optimize the solubility and stability of drugs. Ligand has
established multiple alliances with the world's leading pharmaceutical
companies including GlaxoSmithKline, Merck, Pfizer, Eli Lilly & Company,
Baxter International, Bristol-Myers Squibb, Celgene, Onyx
Pharmaceuticals, Lundbeck Inc., and The Medicines Company, among others.
Please visit www.captisol.com
for more information on Captisol. For more information on Ligand, please
Follow Ligand on Twitter @Ligand_LGND.
[ Back To NFVZone's Homepage ]